Volume 19, Issue 44, July - December, 2025

Evaluation of Nano-Carrier Memantine HCl on Alzheimer's disease-induced by D-Galactose and Aluminum Chloride in rats

Vinoth Kumar R, Sankar C, Sivakumar G^♦

Department of Pharmacology and Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore-48, Tamilnadu, India

^♦Corresponding author
Sivakumar G, Assistant Professor, Department of Pharmacology, KMCH College of Pharmacy, Kalapatti Road, Coimbatore - 641 048, Tamilnadu, India

ABSTRACT

Alzheimer's disease (AD) is a, neurodegenerative disorder develop with slow progression. It is featured by memory loss associated with progressive loss of cognitive function was treated with FDA approved Anti-cholinesterase inhibitors such as Donepezil, Rivastigmine, and NMDA receptor antagonists like Memantine challenged by its limitation to bioavailability and ADR. To improvise the pharmacotherapy of AD we attempted to evaluate the efficacy of nano-Memantine formulation on D-Gal and AlCl3-induced rat model. A Nano Carrier Memantine (NCM) HCl was formulated particle size ranges between 50 to 170 nm and zeta potential value of -30 mV to +30 mV. Moderate increased anti-AD activity emerged for NCM as compared to Memantine HCl with distinguished free radical scavenging for GPx and reduction of MDA with moderate reversal of normal cerebral cortex in contrast to mild therapeutic efficacy for Memantine HCl treated rats. The results emphasize, that NCM HCl might be a good therapeutic alternative for the treatment of AD.

Keywords: Alzheimer's disease, Nano Carrier, Morris Water Maze Test, Open Field Test.

Drug Discovery, 2025, 19(44), e15dd2091

PDF

Published: 07 August 2025